Despite the short-term challenges posed by the COVID-19 pandemic, the US market for interventional oncology devices will grow modestly through 2029. This will be driven largely by the expanding treatable patient populations, an increasing shift towards higher-priced technologies, and growing physician acceptance of interventional oncology procedures. However, growth in this market will be hindered by mixed clinical data and a lack of reimbursement for newer technologies, which has led to a tempered adoption of interventional oncology devices.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in the US across a 10-year period.
The COVID-19 pandemic will have short term consequences on the interventional oncology device market.
How will COVID-19 affect procedure volumes for the different segments of the interventional oncology device market?
When will procedure volumes start to recover and at what rate will the recovery occur?
The patient population eligible for interventional oncology procedures supports growth in the ablation device and embolization particle markets.
What are the fastest growing patient populations eligible for interventional oncology treatments?
What is the clinical evidence supporting the use of ablation or embolization procedures for other cancer indications?
New ablation devices and technologies are rising in popularity among interventional oncologists.
What are the advantages and disadvantages of each type of ablation device?
How has the uptake of microwave ablation affected the market for RF ablation devices?
In which indications will these newer ablation devices, such as cryoablation and IRE, experience the fastest adoption?
Growth in the premium-priced embolization particle segments, such as the DEBs and radioembolization sphere spaces, has slowed in recent years.
What factors have contributed to the slowing growth in these markets?
What are challenges facing physicians and competitors in this space?
How has M&A activity shaped the competitive embolization particles market in recent years?
- Interventional Oncology Devices - Market Insights - United States
Author(s): Kevin Yin, MBA, MBiotech
Kevin Yin is a senior analyst on the Cardiovascular Medtech Insights team at DRG (Part of Clarivate), specializing in the interventional oncology device markets. Kevin holds an MBA from the Ivey Business School at the University of Western Ontario and a Master's degree in Biotechnology from the University of Toronto. Prior to his current position, Kevin worked at Sanofi Pasteur, gaining experience in root cause analysis and compliance strategy.